C
CytomX Therapeutics, Inc. CTMX
$3.48 -$0.72-17.06% NASDAQ
Recommendation
Prev Close
$4.19
Volume
4,782,224
Avg Vol (90D)
3,210,393
Market Cap
$690.99M
Dividend & Yield
--
52-Week Range
$0.40 - $4.62
P/E (TTM)
7.53
EPS (TTM)
$0.56
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
CytomX Therapeutics Inc (CTMX) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline ...
11/7/2025 - GuruFocus
Q3 2025 CytomX Therapeutics Inc Earnings Call Transcript
11/7/2025 - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics (CTMX), AbCellera Biologics (ABCL)
11/7/2025 - TipRanks Financial Blog
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
11/7/2025 - Zacks Investment Research
CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
11/6/2025 - The Fly
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
11/6/2025 - GuruFocus
CytomX Therapeutics Inc Reports Q3 2025 EPS of -$0.09, Revenue at $6.0 Million, Missing Estimates
11/6/2025 - GuruFocus
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
11/6/2025 - Globe Newswire
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
11/6/2025 - MarketBeat
CytomX Therapeutics (CTMX): Assessing Valuation After New CX-801 Data Highlights Immune Activation in Melanoma
11/6/2025 - Simply Wall St
Will CytomX Therapeutics' (CTMX) CX-801 Data Deepen Confidence in Its Immunotherapy Platform?
11/4/2025 - Simply Wall St
CytomX Therapeutics (NASDAQ:CTMX) Shares Up 6% - Still a Buy?
11/4/2025 - MarketBeat
CytomX Therapeutics (CTMX, $3.93) RSI Indicator left the overbought zone on November 03, 2025
11/4/2025 - Tickeron - Stocks
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for ...
11/4/2025 - GuruFocus
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/4/2025 - Globe Newswire
CytomX Therapeutics (NASDAQ:CTMX) Sets New 52-Week High - Still a Buy?
11/4/2025 - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Up 6% - Still a Buy?
11/3/2025 - Ticker Report
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT
10/31/2025 - Insider Monkey
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
10/30/2025 - GuruFocus
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
10/30/2025 - Globe Newswire
14 Stocks Under $5 with Highest Upside Potential
10/30/2025 - Insider Monkey
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX)
10/28/2025 - TipRanks Financial Blog
BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates
10/27/2025 - Zacks Investment Research
CytomX Therapeutics (NASDAQ:CTMX) Given "Hold (C-)" Rating at Weiss Ratings
10/26/2025 - MarketBeat
CytomX Therapeutics management to meet with Oppenheimer
10/24/2025 - The Fly
Income Statement
Total Revenue (TTM)
$141.10M
EBITDA (TTM)
$44.70M
EBIT (TTM)
$43.13M
Net Income (TTM)
$47.98M
Balance Sheet
Total Assets (Q)
$175.06M
Total Debt (Q)
$6.89M
Total Liabilities (Q)
$55.15M
Book Value Per Share (Q)
$0.7271
Cash Flow
Cash from Operations (TTM)
-$77.43M
Cash from Investing (TTM)
-$12.46M
Cash from Financing (TTM)
$95.80M
Net Change in Cash (TTM)
$5.91M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
2.99
7-Day Total Return
6.60%
30-Day Total Return
19.83%
60-Day Total Return
97.44%
90-Day Total Return
40.12%
Year to Date Total Return
227.83%
1-Year Total Return
247.50%
2-Year Total Return
171.48%
3-Year Total Return
178.00%
5-Year Total Return
-49.20%
52-week Low
Apr 07, 2025 - $0.40
52-week High
Nov 06, 2025 - $4.62
Valuation
Market Cap
$690.99M - Small Cap
Enterprise Value
$539.78M
Price/Sales (TTM)
3.83
Price/Book (Q)
5.76
Dividends and Shares
Shares Outstanding
129.08
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.cytomx.com
Phone Number
650 515 3185
Address
151 Oyster Point Boulevard
South San Francisco, CA 94080
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The... more
NASDAQ 11/07/2025 12:37PM Eastern Quotes delayed